Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.33 |
| ▸ | USP1 | O94782 | 3/20 | 0.33 |
| ▸ | WDR48 | Q8TAF3 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14450917 | 0.86 | CYP19A1 (0.43) | KCNA5PTGS2NPC1RAB9A | |
| SCHEMBL1369553 | 0.86 | KCNA5 (0.43) | CYP2A6KCNA5GAAPTGS2USP1 | |
| SCHEMBL1368747 | 0.85 | FEN1 (0.40) | KCNA5GAAPTGS2USP1WDR48 | |
| SCHEMBL1369559 | 0.83 | RPS6KA3 (0.42) | CYP2A6USP1WDR48 | |
| SCHEMBL14450904 | 0.82 | RAB9A (0.38) | CYP2A6KCNA5GAAPTGS2USP1 | |
| SCHEMBL1367002 | 0.82 | KCNA5 (0.45) | KCNA5GAAPTGS2USP1WDR48 | |
| SCHEMBL14450914 | 0.81 | PRKCZ (0.35) | KCNA5GAAPTGS2USP1WDR48 | |
| SCHEMBL14450916 | 0.81 | GPR55 (0.41) | KCNA5GAAPTGS2USP1WDR48 | |
| SCHEMBL14450923 | 0.81 | KCNA5 (0.44) | KCNA5GAANPC1RAB9A | |
| SCHEMBL14450918 | 0.81 | KCNA5 (0.44) | KCNA5KCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067607-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-11-29 | — | — | US | claimed |
| US-20100004229-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2010-01-07 | — | — | US | claimed |
| US-8067607-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100004229-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2010-01-07 | — | — | US | disclosed |
| EP-1993551-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007089735-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089735-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004229-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | CYP2A6 1548/4885KCNA5 20/4885PDK1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.